Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,402.53 -22.32 -0.14%
S&P 500 1,860.07 -2.24 -0.12%
NASDAQ 4,095.88 9.65 0.24%
Ticker Volume Price Price Delta
STOXX 50 3,150.14 10.88 0.35%
FTSE 100 6,617.44 33.27 0.51%
DAX 9,382.50 64.68 0.69%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific Officer


PR Newswire/Les Echos/

PRESS RELEASE

Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific Officer

Paris, France - November 14, 2012 - Sanofi (EURONEXT : SAN ; NYSE : SNY) is pleased to announce today the appointment of Dr. Gary J. Nabel, M.D., Ph.D., Senior Vice President, Chief Scientific Officer and Deputy to the President for Global R&D, effective December 3, 2012. Dr. Nabel will report to Dr. Elias Zerhouni, President, Global R&D, and will join the group's Global Leadership Team. He will be based in Cambridge, Massachusetts.

Dr. Nabel joins Sanofi from the National Institutes of Health, where he served as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases since 1999. During his tenure at the NIH, Dr. Nabel provided overall direction and scientific leadership of the basic, clinical, and translational research activities of the VRC and guides development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including Ebola/Marburg hemorrhagic fevers, influenza, chikungunya and other viruses.

"Dr. Nabel's impressive scientific record and experience will be extremely valuable to the Group", declared Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "I am confident that with his leadership, we can drive R&D further towards tomorrow's breakthrough discoveries."

In his new position, Dr. Nabel will be responsible for assessing and coordinating Sanofi's scientific direction for biopharmaceuticals, vaccines and animal health with a focus on improving translational approaches across Sanofi. In his role, he will lead the evaluation of scientific quality of projects and programs across all of R&D, and participate in setting Sanofi's overall strategy

"I am very excited that Dr. Nabel will join Sanofi's R&D organization", said Dr. Elias Zerhouni, President, Global R&D, Sanofi. "Our challenges today require that we re-invent our R&D model. Gary's experience will be invaluable to help us achieve this goal."

"I am honored and excited to join Dr. Zerhouni and the Sanofi team", said Dr. Gary Nabel. "By strengthening our scientific base, we hope to accelerate the rational development of innovative treatments that will save lives and improve human health."

Dr. Gary J. Nabel Biography Dr. Nabel has an extensive and distinguished background of academic and hospital appointments, and committee memberships including numerous prestigious awards and honors and an extensive publication record. He graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard University, completing his Ph.D. in 1980 and his M.D. in 1982. He served as a postdoctoral fellow in the laboratory of David Baltimore at MIT's Whitehead Institute. Before his appointment at the Vaccine Research Center, Dr. Nabel served as the Henry Sewall Professor of Internal Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute Investigator at the University of Michigan in Ann Arbor. In addition to his faculty positions, Dr. Nabel also served as the Director of the Center for Gene Therapy and co-director of the Center for Molecular Medicine at the University of Michigan. In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Dr. Nabel was elected as a member of the Institute of Medicine of the National Academy of Sciences in 1998.

About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts: Media Relations Investor Relations Jean-Marc Podvin Sébastien Martel Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45 mr@sanofi.comir@sanofi.com

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Nov/14/2012 15:09 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement